Booz Allen to Help FDA Modernize the Human Drug Review Process

Driven by its responsibility to protect and promote public health, the U.S. Food and Drug Administration (FDA) ensures that patients and providers have timely and continued access to safe, effective, and high-quality medical products. To advance that mission, in October of 2017, the FDA’s Center for Drug Evaluation and Research (CDER) awarded Booz Allen Hamilton (NYSE: BAH) one of two spots on a competitive, $300 million Blanket Purchase Agreement (BPA) over seven years to support its implementation of a transformational Informatics Platform that will enable the Agency to bring life-saving drugs to market with greater speed and efficiency. 

External News Article: 
Add reference to external site news article
News Category: 
Member News